NanoGuardian™, a division of NanoInk®
that works with pharmaceutical manufacturers in delivering brand protection
solutions to protect against illegal diversion and counterfeiting, announced
today the extension of its state-of-the-art NanoEncryption™ technology
in covering single-use vial caps and pre-filled syringes to help ensure the
safety of products using these delivery systems. This announcement follows NanoGuardian's
recent licensing agreement with Capsugel®, a division of Pfizer, for the
protection of capsule-based medications.
Prescription pharmaceutical products delivered in vials and pre-filled syringes
are a target for counterfeiters and illegal diverters. In the book "Dangerous
Doses," by Katherine Eban, criminals placed counterfeit product labels
indicating a higher strength on illegally diverted low-dose vials of medicines.
These adulterated, mis-labeled medications penetrated the legitimate supply
chain and were taken unknowingly by patients. NanoGuardian's NanoEncryption
technology in conjunction with its Closed-Loop Protection™ market monitoring
program can assist manufacturers in protecting each vial or syringe against
NanoEncryption technology protects against both counterfeiting and illegal
diversion by providing a layered security solution consisting of overt, covert
and forensic-level security features. The overt and covert security features
allow dose-level authentication at any point in a manufacturer's supply chain,
while the forensic-level NanoCodes™ provide unlimited information on each
and every dose, including dosage strength, expiration date, date of manufacture,
manufacturing location, country of distribution, etc. NanoGuardian's technology
provides a strong benefit over other on-dose technologies given that NanoGuardian's
security features are implemented with no additional chemicals being added to
the medication. Additionally, NanoGuardian's Closed-Loop Protection combines
the on-dose authentication and tracing benefits of NanoEncryption technology
with a proactive pharmacy auditing program to identify counterfeit or illegally-diverted
pharmaceuticals entering the global supply chain.
"Given the significant potential for negative impact to patients' well
being, we are pleased to extend our NanoEncryption technology to single-use
vial caps and syringes. This extension provides pharmaceutical manufacturers
a new, high-tech tool to help ensure the safety of their products using these
delivery systems," said Dean Hart, executive vice president of NanoGuardian.
According to the U.S.-based Center for Medicines in the Public Interest (CMPI),
counterfeit drug commerce is estimated to grow 13 percent annually through 2010.
"That means counterfeit drug sales will grow at nearly twice the rate of
legitimate pharmaceutical commerce," said Peter Pitts, President of CMPI.
"In 2010, this illegal business will generate $75 billion in revenues -
a 92 percent increase from 2005."